New Zealand-based medtech tech developer, Adherium, has entered into a long term partnership with AstraZeneca to supply new devices and sensors that AstraZeneca will incorporate within global patient support programs for COPD and asthma.
Mr Garth Sutherland, managing director and CEO, Adherium said, "We are very pleased to be working with AstraZeneca. These agreements represent a major advance in the treatment and management of respiratory disease, and will make a fundamental difference to the quality of life for people with asthma and COPD."
This provides objective data on inhaler medication use to patients, physicians and carers. AstraZeneca has used this technology in clinical evaluations and clinical trials, and has piloted its use in programs to support patients in the management of their conditions.
AstraZeneca plans to use Adherium device technology as the pivotal component of its innovative global patient support programs. Initially the technology will be used to monitor patients' use of therapy and provide personalised advice to patients based on their conditions and medication use. In the future, developments are likely to include additional sensors designed to monitor a patient's condition and potentially to assess a patient's personalised risk factors.
Dr Doug Wilson, chairman, Adherium, commented, "This partnership signifies a change in the way we approach the treatment of respiratory disease. By providing objective and accurate data on a patient's medication usage, we can now for the first time develop treatment plans tailored to each patient, and in doing so dramatically improve their quality of life."